Related references
Note: Only part of the references are listed.The ferret as a model organism to study influenza A virus infection
Jessica A. Belser et al.
DISEASE MODELS & MECHANISMS (2011)
MF59 adjuvant: the best insurance against influenza strain diversity
Derek T. O'Hagan et al.
EXPERT REVIEW OF VACCINES (2011)
Use of defined TLR ligands as adjuvants within human vaccines
Malcolm S. Duthie et al.
IMMUNOLOGICAL REVIEWS (2011)
Influenza vaccine immunology
Philip R. Dormitzer et al.
IMMUNOLOGICAL REVIEWS (2011)
H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
Philippe Moris et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Protective B Cell Responses to Flu-No Fluke!
Elizabeth E. Waffarn et al.
JOURNAL OF IMMUNOLOGY (2011)
Hallmarks of CD4 T cell immunity against influenza
K. K. McKinstry et al.
JOURNAL OF INTERNAL MEDICINE (2011)
A fast track influenza virus vaccine produced in insect cells
Manon M. J. Cox et al.
JOURNAL OF INVERTEBRATE PATHOLOGY (2011)
Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
Rhea N. Coler et al.
PLOS ONE (2011)
Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88
Anja Seubert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets
Benoit Baras et al.
VACCINE (2011)
Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes
Samuele Calabro et al.
VACCINE (2011)
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial
John J. Treanor et al.
VACCINE (2011)
H5N1 Avian Influenza: Preventive and Therapeutic Strategies Against a Pandemic
Suryaprakash Sambhara et al.
ANNUAL REVIEW OF MEDICINE (2010)
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations
Ryan C. Anderson et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2010)
Molecular Characterization of In Vivo Adjuvant Activity in Ferrets Vaccinated against Influenza Virus
Yuan Fang et al.
JOURNAL OF VIROLOGY (2010)
Quantifying the Early Immune Response and Adaptive Immune Response Kinetics in Mice Infected with Influenza A Virus
Hongyu Miao et al.
JOURNAL OF VIROLOGY (2010)
A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines
Rhea N. Coler et al.
PLOS ONE (2010)
Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data
Geert Leroux-Roels
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Evaluation of Vaccines for H5N1 Influenza Virus in Ferrets Reveals the Potential for Protective Single-Shot Immunization
Deborah Middleton et al.
JOURNAL OF VIROLOGY (2009)
MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)
Barbara C. Baudner et al.
PHARMACEUTICAL RESEARCH (2009)
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels
Grazia Galli et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
New horizons in adjuvants for vaccine development
Steven G. Reed et al.
TRENDS IN IMMUNOLOGY (2009)
Enhanced humoral and Type 1 cellular immune responses with Fluzone® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion
Susan L. Baldwin et al.
VACCINE (2009)
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
JJ Treanor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
CD4 T cell-mediated protection from lethal influenza: Perforin and antibody-mediated mechanisms a one-two punch
Deborah M. Brown et al.
JOURNAL OF IMMUNOLOGY (2006)
Roles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection:: Evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity
K Mozdzanowska et al.
JOURNAL OF VIROLOGY (2005)
Share Paper
